There is currently no treatment for RUNX1 familial platelet disorder (RUNX1-FPD). However, this year marks a significant milestone with the […more…]
Despite living with RUNX1 familial platelet disorder (RUNX1-FPD), Tim Babich lived a happy life with his wife, Monica. After the […more…]
RUNX1 Research Program
www.runx1-fpd.org
(916) 212-0410
Director of Development : Alex Gonzalez
Mission
To improve the quality of life and prevent cancer in patients with RUNX1-FPD. We do this by promoting awareness and funding world-class collaborative research with an empowered patient community.
Begin to Build a Relationship
We know you care about where your money goes and how it is used. Connect with this organization’s leadership in order to begin to build this important relationship. Your email will be sent directly to this organization’s Director of Development and/or Executive Director.
Before we started the RUNX1 Research Program, we didn’t know of anyone else having RUNX1-FPD beyond our family – but we knew others like us were out there, waiting to be found. Over the past six years, we’ve close to 400 patients join our community from across the world, and we know there are so many more. We are proud that RRP has granted over $11M to support 31 research projects towards finding a cure to benefit all our families.
Stop Cancer in Its Tracks
As part of their mission to stop cancer in its tracks, all donations to the RUNX1 Research Program fund cancer prevention initiatives – a mission that has never been more important. Medical professionals predict that, in the next year, cancer will become the number one cause of death in the United States. Your donations to the RUNX1 Research Program will fund research at the forefront of cancer detection and intervention. By studying the earliest signs of cancer today, we can prevent a fatal diagnosis tomorrow.
Key Supporters
Tim and Monica Babich
Georgetta and Charles Blackburn
Alex’s Lemonade Stand Foundation
The Edward P. Evans Foundation
Leukemia & Lymphoma Society
Mark Foundation for Cancer Research
NeoGenomics
Chan Zuckerberg